What is KLOW peptide?

KLOW peptide is not one molecule. It is a research blend of four peptides co-formulated in a single vial — GHK-Cu, KPV, BPC-157 and TB-500 — which most US suppliers sell at 80mg in total, split 50/10/10/10mg. "KLOW" is a market label shared by many vendors rather than a standard, so the name tells you which four compounds to expect but says nothing binding about how much of each is in the vial. This guide covers what is inside, why the milligram split and the molecule count tell two different stories, why the solution is blue, what the published research on each component actually covers, and what to check when buying KLOW in the United States. We sell it as the Klow Stack.

Research use only. The Klow Stack is supplied strictly for in-vitro laboratory research. It is not for human or veterinary use and has not been evaluated by the FDA. This guide does not describe dosing, administration or effects in people or animals.

What's inside an 80mg KLOW vial

Ours arrives as one pre-mixed solution in a sealed vial. The molecular weights are for the free peptides as listed in our specifications; salt forms and counter-ions move them slightly, which is one reason a batch's certificate, rather than a reference sheet, is the document that describes the material actually in the vial.

Same milligrams, different molecule counts

Most listings describe KLOW only by mass, and by mass three of the four components look identical at 10mg each. Counted as molecules they are far apart. Dividing each mass by its molecular weight gives the amount of substance in one 80mg vial:

Put another way: for every BPC-157 molecule in the vial there are roughly four KPV molecules, about one and a half TB-500 molecules and about eighteen GHK-Cu complexes. The reason is size. KPV is about a quarter the mass of BPC-157, so ten milligrams of it is four times as many molecules.

This matters as soon as the blend is compared against single-compound controls. Controls matched milligram-for-milligram reproduce the blend's mass split but not its molecular one; controls matched by micromole do the reverse. Neither convention is wrong, but a protocol should state which one it used — and results from two suppliers' KLOW are only comparable once you have confirmed the two vials share the same 50/10/10/10 split in the first place.

Why KLOW is blue

A correctly made KLOW solution is blue, and the color comes entirely from GHK-Cu. The copper(II) ion is held by the tripeptide's nitrogen donors — the free amino group of glycine, the deprotonated amide nitrogen next to it and the imidazole ring of histidine — and copper(II) bound that way absorbs part of the visible spectrum and leaves a blue cast. KPV, BPC-157 and TB-500 are colorless in solution, so they contribute nothing to it.

That makes color a quick first look at the copper component: a KLOW that arrives colorless is worth questioning before anything else. It is not an assay. Color says the copper complex is present; it does not say how much of each of the four peptides is there, and it says nothing at all about the three colorless ones.

What the published research on each component covers

The published work on all four compounds is preclinical — cultured cells and animal models — and its findings belong to those systems.

• GHK-Cu. Most of the literature is cell work — fibroblasts, keratinocytes and other cultured lines — together with gene-expression analyses cataloguing which genes shift when GHK is present. Pickart and Margolina's 2018 review collects that gene-expression data.
• KPV. Studied as the smallest C-terminal fragment of α-MSH. A 2004 study examined its intracellular signaling in human keratinocyte cells and found calcium responses but no rise in cyclic AMP. A 2008 study showed that intestinal epithelial and immune cells take KPV up through the peptide transporter PepT1, and examined it in mouse models of chemically induced intestinal inflammation. The KPV guide has more.
• BPC-157. A large body of rodent work on tissue models. A 2019 review of the musculoskeletal portion noted that most studies used small rodent models, that efficacy has not been confirmed in humans, and that only a handful of research groups have studied the peptide in depth.
• TB-500. Thymosin β4 is a 43-residue protein that binds G-actin, and the LKKTETQ stretch at positions 17-23 is the actin-binding motif TB-500 is built around. TB-500 is the fragment, not the full protein; mass spectrometry tells the two apart at once.

No controlled study of the four compounds together has been published. Anything said about what "KLOW does" is therefore assembled from separate single-compound papers, run in different models at different concentrations.

KLOW, GLOW or Wolverine: choosing by research question

The three blends nest inside one another, so the choice comes down to which components the work actually needs:

• The question involves BPC-157 and TB-500 only — the two-compound Wolverine Stack is the cleaner preparation.
• Copper-peptide signaling is part of the design — the Glow Stack adds GHK-Cu to that pair.
• The α-MSH fragment is needed as well — KLOW is GLOW with KPV added.
• Any one component has to vary on its own — none of the blends will do, because nothing in a sealed co-formulation can be adjusted independently. GHK-Cu, BPC-157 and TB-500 are sold as single vials.

Pre-mixed or powder

Much of the KLOW listed in the US is lyophilized powder, which means every vial passes through a reconstitution step in someone's laboratory — four solutes going into solution at their own rates, where an incompletely dissolved vial no longer delivers its stated split. A pre-mixed KLOW has its ratio fixed when the solution is made. The cost is handling: a solution has to be kept at 2-8°C, travel cold-chain and never be frozen. The pre-mixed vs lyophilized guide compares the two formats in detail.

Buying KLOW in the United States

Whoever you buy from, a KLOW listing should tell you, before you pay:

1. All four components and the amount of each — "80mg" on its own is a total, not a specification.
2. The format — pre-mixed solution or powder, since they are stored and handled differently.
3. A batch-specific certificate that names each component and the analytical method, with a batch number that matches the vial.
4. Storage and shipping — cold-chain for a solution.
5. A plain research-use position — no outcome language, no dosing, no implication of FDA approval.

Our Klow Stack ships pre-mixed, cold-chain from the warehouse that serves the United States, with tracked delivery across the country next business day. It is priced in US dollars and payable by Visa, Mastercard or Apple Pay, and batch certificates sit in our COA library — the Certificate of Analysis guide explains how to read one. We also ship outside the United States; delivery is quoted at checkout.

Where KLOW stands in the US

• Not an approved drug. KLOW, and each of its four components, is not an FDA-approved drug and has not been evaluated by the FDA. It is sold for in-vitro laboratory research and not for human or veterinary use.
• Anti-doping. BPC-157 and TB-500 both appear on the WADA Prohibited List, which matters to anyone working under anti-doping rules.

Dosing

We do not publish dosing, reconstitution-for-use or administration information for KLOW or any of its components. The material is supplied for in-vitro research, and concentrations in published work are specific to each model and endpoint — the primary literature is the place to look for them.

Related reading

• What is GHK-Cu? · What is KPV? · What is the Glow Stack? · What is the Wolverine Stack? · Pre-mixed vs lyophilized peptides